Los datos de PECHO del 21 de octubre de 2026 cubrían molgramostim. Las acciones de Savara se enfrentan al 22 de noviembre de 2026, decisión de la FDA

YARDLEY, Pa., October 21, 2026--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the CHEST 2026 Annual Meeting in Phoenix, Arizona. The poster reports a post-hoc analysis of the IMPALA clinical trial evaluating the effects of molgramostim in aPAP patients with mildly decreased or normal diffusion capacity, defined as a baseline percent predicted hemoglobin-adjusted diffusing capacity of the lungs for

Savara presented molgramostim data on October 12, 2026 for CHEST. Savara stock costs EUR 4.17 on Oct

The November 22 FDA decision on MOLBREEVI sets the next test for Savara stock. Q3 2026 results are e

Savara will present IMPALA data at CHEST 2026 on October 18-21, 2026. Savara stock costs EUR 4.28 on

Savara Inc. reported that CHEST 2026 accepted an encore oral presentation from its Phase 3 IMPALA-2 trial and a poster from its Phase 2/3 IMPALA study, both focused on molgramostim in autoimmune pulmonary alveolar proteinosis. The dual focus on long term efficacy, safety and treatment effects in patients with mild diffusion impairment highlights how central molgramostim is to Savara’s development efforts and future operating profile. We will look at how Savara’s investment narrative is...

Savara Inc. announced that CHEST 2026 accepted an encore oral presentation on Phase 3 IMPALA-2 data and a poster on Phase 2/3 IMPALA molgramostim data in autoimmune pulmonary alveolar proteinosis, both to be presented in Phoenix, Arizona, on October 18–21, 2026. The focus on long-term efficacy and safety, plus outcomes in patients with mild diffusion impairment, highlights how comprehensively molgramostim is being evaluated for autoimmune pulmonary alveolar proteinosis. With this fresh focus...

Savara Inc. reported that CHEST 2026 accepted an encore oral presentation from its Phase 3 IMPALA-2 trial and a poster from its Phase 2/3 IMPALA study, both focused on molgramostim in autoimmune pulmonary alveolar proteinosis. The dual focus on long term efficacy, safety and treatment effects in patients with mild diffusion impairment highlights how central molgramostim is to Savara’s development efforts and future operating profile. We will look at how Savara’s investment narrative is...

Key TakeawaysJPMorgan started coverage of Savara on Oct. 7 with an Overweight rating and a $12 target, 146% above the $4.

Las acciones de Savara se enfrentan a una decisión de la FDA el 22 de noviembre de 2026 después de que el BPA ajustado del segundo trimestre fuera de -0,16 dólares frente a